ST. PETERSBURG, Fla., Aug. 25, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corp. (the "Company") (NASDAQ:ISLE, ISLEW))) today announced that it has cancelled its special meeting of shareholders that was previously scheduled for August 26, 2022, and that it will redeem all of its outstanding ordinary shares that were included in the units issued in its initial public offering (the "public shares"), effective as of the close of business on August 29, 2022, as the Company will not consummate an initial business combination on or prior to September 1, 2022. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combinati

ST. PETERSBURG, Fla., June 30, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corporation (NASDAQ:ISLE)("Isleworth"), a special purpose acquisition company, today announced that it has entered into an agreement with Cytovia Holdings, Inc. ("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies (the "Termination Agreement") to terminate its previously announced Merger Agreement with Cytovia, which was executed in April 2022. The Termination Agreement is effective immediately, and contains mutual releases and covenants not to sue. A copy of the Termination Agreement is filed as an exhibit to

Data supports further development of CYT-338 in relapsed/refractory multiple myeloma AVENTURA, Fla. and NATICK, Mass., June 10, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association's annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites. For details on in-person poster presentations, please see the

AVENTURA, Fla. and NATICK, Mass., May 18, 2022 /PRNewswire/ -- Cytovia Therapeutics,  LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the the Annual European Hematology Association's (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022 at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online.  The abstract was released on May 12, 2022. The e-poster present

AVENTURA, Fla. and NATICK, Mass., May 6, 2022 /PRNewswire/ -- Cytovia Therapeutics,  LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer, to be held from May 5-8, 2022, at the Westin Copley Place in Boston, Massachusetts. The conference is an in-person event and will not live-stream content, but Cytovia Therapeutics's short poster video will be available for on-demand viewing by conference registrants aft

Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cellsCytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreement and combined company is expected to be listed on NASDAQ under the ticker symbol INKC$20 million note represents upfront collaboration consideration and would convert into common stock upon completion of the business combination NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces today that its part

In conjunction with the business combination agreement, the parties have commitments for $40 million in new investments by institutional investors, including $20 million in conversion of licensing consideration from CellectisIsleworth has $207 million in trustMerger expected to be completed in Q3 of 2022; Combined company expected to be listed on NASDAQ under the ticker symbol INKC.ST. PETERSBURG, Fla. and AVENTURA, Fla. and NATICK, Mass., April 26, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corp. (NASDAQ:ISLE) ("Isleworth"), a special purpose acquisition company (NASDAQ:ISLE, ISLEW))) and Cytovia Holdings, Inc.("Cytovia"), a biopharmaceutical company empowering natural killer (NK

ST. PETERSBURG, Fla., June 3, 2021 /PRNewswire/ -- Isleworth Healthcare Acquisition Corp. (NASDAQ: ISLE) (the "Company") announced today announced that on May 28, 2021 it received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the "Form 10-Q") with the Securities and Exchange Commission ("SEC"). The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market.  As previously disclos

4 - Isleworth Healthcare Acquisition Corp. (0001837997) (Issuer)

3 - Isleworth Healthcare Acquisition Corp. (0001837997) (Issuer)

SC 13G - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)